Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated MilestonesPRNewsWire • 09/09/24
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)PRNewsWire • 08/28/24
First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of ObesityPRNewsWire • 08/22/24
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross ProceedsPRNewsWire • 06/21/24
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)PRNewsWire • 06/20/24
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of ObesityPRNewsWire • 06/12/24
Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 05/20/24
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdatePRNewsWire • 05/15/24
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024PRNewsWire • 05/09/24
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of ObesityPRNewsWire • 05/02/24
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024PRNewsWire • 04/30/24
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024PRNewsWire • 04/08/24
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)PRNewsWire • 02/28/24
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdatePRNewsWire • 02/15/24
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024PRNewsWire • 02/09/24
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)PRNewsWire • 02/05/24
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024PRNewsWire • 01/08/24
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.Business Wire • 01/03/24